MorphoMed MorphoMed is a Vienna-based preclinical medical-technology company developing biodegradable silk biomaterial implants for tissue regeneration. Its silk scaffolds are designed to support tendon and ligament repair, with rotator-cuff repair identified as its first medical indication in a 2026 company recruitment posting. Its wider development work includes cruciate-ligament grafts, nerve guidance conduits and methods for concentrating a patient’s own regenerative cells. The company develops and tests materials that provide a temporary structure for new tissue to grow as the implant degrades; published rotator-cuff results are from animal studies, rather than approved clinical use.
Founded 2017
Eva Mair Research Staff (employment disclosed in July 2026 publication) Heinz Redl Research Staff (employment disclosed in July 2026 publication) Sandra Milić Research Staff (employment disclosed in July 2026 publication)
SHOW MORE
team@apexlogos.ai · 24 hours ago
Published team evidence and gaps: Current own website serves legal imprint and authentic logo; former/about,/team and product paths returned404 during this review. Search-index copies of an older own seven-person directory are preserved as historical leads, not proof of current employment. In particular, old Bernhard Küenburg — Head of Business Development,Udo Elsner — Corporate Legal Affairs,Michael Hammerschmid — Head of QM and Manufacturing,Thomas Nau — CMO andHeinz Redl — Scientific Advisory Board Chair are not restored without current confirmation. Current institutional page verifies Andreas Teuschl-Woller — Co-founder and CSO; ORS 2026 authors disclose Thomas Nau — Co-founder. Its shareholder disclosure conflicts with official register soleILUM shareholder, so no direct individual ownership is structured. July 17, 2026 primary research publication explicitly discloses that Marie-Sophie Narzt,Sandra Milić,Eva Mair,Michael Jakusch andHeinz Redl were employed by MorphoMed. The four research-staff roles are qualified by that publication date, without guessed precise job titles or an assertion of continued October employment. BernhardKuenburg andHeinzRedl nativepersons are reused based on exact identity and linked current ILUM, UpNano and Regenera tissue-regeneration context; AndreasTeuschl-Woller is the published current name, with older Andreas Teuschl retained as an identity lead. A complete company-published current employee/board/SAB roster remains unavailable.
Sources:
https://www.morphomed.at/
https://www.morphomed.at/about
https://www.evi.gv.at/f/472043g
https://www.technikum-wien.at/personal/andreas-teuschl-woller/
https://www.ors.org/wp-content/uploads/AM26/760.pdf
https://www.frontiersin.org/journals/bioengineering-and-biotechnology/articles/10.3389/fbioe.2026.1869470/full SHOW MORE
team@apexlogos.ai · 24 hours ago
Identity, product status and ownership precision: MorphoMed GmbH FN472043g, Vienna, was incorporated May 25, 2017. It is distinct from university educational anatomy software also called MorphoMed. Current official register names Michael Jakusch managing director and Bernhard Küenburg authorized signatory, and ILUM Tec GmbH sole shareholder, enteredJuly 23, 2021. Nominal EUR 62,200 registered share capital is not financing raised, ticket or valuation. January 9, 2026 registry lists a merger event but does not show counterpart/terms on its summary; no merger financing or acquisition amount is inferred. The current ILUM holding is represented with unknown financing terms and no fund vintage allocation. Company recruitment for Q2 2026 says preclinical, preparing first indication rotator-cuff repair for the US market and not ISO-certified at posting. Neither ISO certification, human trial enrollment nor FDA/CE clearance is asserted. ORS 2026 rotator-cuff study is a sheep-model experiment, not clinical efficacy proof.
Sources:
https://www.evi.gv.at/f/472043g
https://at.linkedin.com/jobs/view/qms-manager-m-f-d-at-morphomed-gmbh-4361788040
https://www.ors.org/wp-content/uploads/AM26/760.pdf
https://ilumtec.at/en/#morphomed SHOW MORE
